Market Overview

UPDATE: Wedbush Securities Initiates Coronado Biosciences at Outperform on Outlook for CNDO-201

Related CNDO
Coronado Falls on TSO Study Results - Analyst Blog
Pipeline Progress at Coronado Biosciences - Analyst Blog
Coronado Biosciences (CNDO) Jumps: Stock Rises 10.7% - Tale of the Tape (Zacks)

Wedbush Securities initiated coverage on Coronado Biosciences (NASDAQ: CNDO) with an Outperform rating and a $13 price target.

Wedbush Securities commented, "We believe that CNDO-201 is likely to find substantial use in the 40% of patients with inflammatory bowel disease (IBD) that fail last-line TNF-alpha therapy. Moreover, given the drawbacks and growing concerns about the safety of TNF-alpha's and corticosteroids, we believe that CNDO-201, driven by superior safety and tolerability, could displace TNF-alpha therapies and be used in combination with current first-line therapies in IBD, a market worth >$4 billion."

Coronado Biosciences closed at $4.79 on Wednesday.

Latest Ratings for CNDO

Nov 2013Bank of AmericaDowngradesNeutralUnderperform
Oct 2013MLV & Co.DowngradesBuyHold
Oct 2013WedbushDowngradesOutperformNeutral

View More Analyst Ratings for CNDO
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (CNDO)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content